UChicago Medicine and its Comer Children's Hospital have both been recognized by Newsweek as top-ranked hospitals in the magazine's America’s Best Hospitals lists for 2023, including recognition on the lists for best cancer hospitals, best maternity hospitals and best children’s hospitals.
Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.
Findings from a breast cancer analysis demonstrated that pathologic complete response and event-free survival rates were not significantly affected by patient’s race.
In this episode of “The Vitals,” 2 health care professionals discuss how to safely celebrate the holidays in oncology units.
Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.
“We want to make sure we can provide the right treatment for the right patient at the right time,” says Olufunmilayo I. Olopade, MD, FACP, OON.
Nearly 1 year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to Rita Nanda, MD.
The treatment landscape of ovarian cancer continues to change with the recent approvals of new agents.
